Purpose There is a need for diagnostic and prognostic biosignatures to improve long-term outcomes in inflammatory bowel disease (IBD). Here, we describe the establishment of the Swedish Inception ...

FILSPARI holds strong market potential as the first FDA-approved non-immunosuppressive therapy for IgA nephropathy, a rare kidney disease with significant unmet needs. As more patients and providers ...

DelveInsight's "FILSPARI Market Size, Forecast, and Market Insight Report" highlights the details around FILSPARI, the first ...

Hyperkalemia increases risk of cardiac arrhythmias and death and limits the use of renin-angiotensin-aldosterone system inhibitors and mineralocorticoid receptor antagonists, which improve clinical ...

12 Underscoring the importance of the NICE recommendation for IgA nephropathy patients and their communities, Dr. Vinicius Gomes De Lima, Head of Global Medical Affairs at CSL Vifor said ...

Zealand Pharma A/S + Watchlist ZEAL DK Closed Last Updated: May 23, 2025 5:20 p.m. CEDT Delayed quote kr. 408.90 4.40 1.09% Previous Close kr.404.50 Toggle Chart Options Advanced Charting ...

On 14 December 2021, CSL announced its intention to acquire Vifor Pharma, an iron deficiency and nephrology treatment company, for US$11.7 billion. That acquisition was completed on 9 August 2022.

Six so-called patient advocacy groups are working to advance corporate profits in the pharmaceutical industry by routinely lobbying in line with Big Pharma’s priorities and opposing drug price ...

May 21 (Reuters) - Indian drugmaker Mankind Pharma (MNKI.NS), opens new tab reported a fourth-quarter profit that beat analysts' estimates on Wednesday, driven by strong domestic demand for its ...

(Reuters) -Indian drugmaker Mankind Pharma reported a fourth-quarter profit that beat analysts' estimates on Wednesday, driven by strong domestic demand for its drugs to treat long-term illnesses. The ...